Over the past decade, small molecule kinase inhibitors have emerged as promising therapeutics, particularly in oncology. Through data that has emerged during this period, it has become increasingly ...

Lipid kinases are among the promising targets of new classes of drugs, due mainly to class I PI3Kα, which plays a crucial role in carcinogenesis and metastasis. This enzyme is hyperactive in 30-40% of ...

A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...

The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...